On this page of StockholderLetter.com we present the latest annual shareholder letter from REGENERON PHARMACEUTICALS, INC. — ticker symbol REGN. Reading current and past REGN letters to shareholders can bring important insights into the investment thesis.

 •  4/29/2025 Letter Continued (Full PDF)
 •  4/21/2023 REGN Stockholder Letter
 •  4/25/2024 REGN Stockholder Letter
 •  More "Biotechnology" Category Stockholder Letters
 •  REGN Benford's Law Stock Score = 75

REGN Shareholder/Stockholder Letter Transcript:

REGENERON BY THE NUMBERS
14
medicines approved
in the United States
or other countries
~50
countries with
clinical trials
15.1K+
12
approvals for additional
indications or populations
for existing products in the
United States, European
Union, and Japan in 2024
100K+
eligible patients given
~$3.4B* worth of
medicine at no cost
through our products   
patient assistance
programs in 2024
Regeneron colleagues
worldwide at
2024 year-end
52%
employee volunteerism
rate in 2024
* Based on 2024 year-end wholesale acquisition cost
~40
product candidates
in clinical development
~3M
exomes sequenced
to date by Regeneron
Genetics Center  
~3.2M
students supported
by Regeneron STEM
initiatives since 2020

FORM 10-K



 4/29/2025 Letter Continued (Full PDF)